NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637955. A total of 2 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $7,000 | – | 148 | +1380.0% | 0.00% | – |
| Q2 2020 | $0 | -100.0% | 10 | -89.6% | 0.00% | – |
| Q1 2020 | $5,000 | -82.8% | 96 | -57.7% | 0.00% | – |
| Q4 2019 | $29,000 | +31.8% | 227 | +102.7% | 0.00% | – |
| Q3 2019 | $22,000 | +214.3% | 112 | +286.2% | 0.00% | – |
| Q2 2019 | $7,000 | -22.2% | 29 | -27.5% | 0.00% | – |
| Q1 2019 | $9,000 | +200.0% | 40 | +233.3% | 0.00% | – |
| Q3 2018 | $3,000 | -88.9% | 12 | -84.6% | 0.00% | – |
| Q2 2018 | $27,000 | – | 78 | +3800.0% | 0.00% | – |
| Q1 2018 | $0 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |